The National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health has partnered with the pharmaceutical company GlaxoSmithKline (GSK) to boost the development of a candidate Ebola vaccine that uses a modified chimpanzee adenovirus to deliver viral glycoprotein antigens. Following the demonstration that the vaccine protected non-human primates from Ebola infection, the NIAID began a Phase 1 trial of the vaccine at the NIH Clinical Center in Bethesda, Maryland, in September.
Researchers reported last week (November 26) in The New England Journal of Medicine that the vaccine elicited immune responses in 20 adult volunteers who received two different doses and did not cause serious adverse events. The vaccine is on track to be tested in health-care workers in West Africa ...
